文献速递癫痫

育龄期癫痫女性的抗癫痫药物处方模式

Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
PubMed 文献 · JAMA Neurol · 2019-01-01

结果显示,尽管丙戊酸钠和托吡酯有致畸风险,仍被广泛用于育龄期癫痫女性,且合并症影响药物选择。

要点

  • 育龄期癫痫女性中丙戊酸钠和托吡酯的使用仍常见,需关注致畸风险。
  • 合并头痛或偏头痛、情绪障碍等合并症时,丙戊酸钠和托吡酯使用比例更高。
  • 多数新诊断患者首选单药治疗,但部分患者未记录AED治疗。

核心结论

  • 尽管已知丙戊酸钠和托吡酯有致畸风险,许多育龄期癫痫女性仍在使用这些药物。
  • 合并症可能影响特定AED的选择,即使这些药物存在致畸风险。

研究设计与样本

  • 回顾性队列研究,使用全国商业数据库及补充的Medicare和Medicaid保险索赔数据。
  • 新发病例定义为基线至少2年无癫痫诊断或AED处方,并与流行病例按年龄、保险类型和入组时间匹配局灶性和全面性癫痫队列。

主要发现

  • 在3,219例接受AED治疗≥90天的新发病例中,3,173例(98.6%)首次治疗为单药治疗。
  • 3,544例(44.3%)新发病例和9,480例(24.5%)流行病例在诊断后≥180天随访期间未记录AED治疗。
  • 新发病例中,丙戊酸钠使用率5.81%,流行病例中13.1%;苯妥英新发5.48%,流行4.53%;奥卡西平新发8.03%,流行9.89%。
  • 左乙拉西坦、拉莫三嗪和托吡酯是局灶性和全面性癫痫最常用的AED。

关键数值与推荐

  • 丙戊酸钠在合并头痛或偏头痛、情绪障碍、焦虑和分离障碍的女性中更常被处方。
  • 托吡酯在合并头痛或偏头痛的女性中更常被处方(新发26.8%,流行28.9%)。

临床怎么用

  • 临床医生为育龄期癫痫女性处方AED时,应权衡致畸风险,尤其在使用丙戊酸钠和托吡酯时。
  • 需关注合并症对AED选择的影响,避免因合并症而增加致畸风险药物的使用。

局限性

  • 研究为回顾性设计,可能存在处方记录不全或误分类。
  • 数据来源为保险索赔数据库,可能无法完全反映临床实际情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited population-based data are available on antiepileptic drug (AED) treatment patterns in women of childbearing age with epilepsy; the current population risk is not clear. OBJECTIVES: To examine the AED treatment patterns and identify differences in use of valproate sodium and topiramate by comorbidities among women of childbearing age with epilepsy. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study used a nationwide commercial database and supplemental Medicare as well as Medicaid insurance claims data to identify 46 767 women with epilepsy aged 15 to 44 years. The eligible study cohort was enrolled between January 1, 2009, and December 31, 2013. Data analysis was conducted from January 1, 2017, to February 22, 2018. EXPOSURES: Cases required an International Classification of Diseases, Ninth Revision, Clinical Modification-coded epilepsy diagnosis with continuous medical and pharmacy enrollment. Incident cases required a baseline of 2 or more years without an epilepsy diagnosis or AED prescription before the index date. For both incident and prevalent cases, focal and generalized epilepsy cohorts were matched by age, payer type, and enrollment period and then compared. MAIN OUTCOMES AND MEASURES: Antiepileptic drug treatment pattern according to seizure type and comorbidities. RESULTS: Of the 46 767 patients identified, there were 8003 incident cases (mean [SD] age, 27.3 [9.4] years) and 38 764 prevalent cases (mean [SD] age, 29.7 [9.0] years). Among 3219 women in the incident epilepsy group who received AEDs for 90 days or more, 3173 (98.6%) received monotherapy as first-line treatment; among 28 239 treated prevalent cases, 18 987 (67.2%) received monotherapy. In 3544 (44.3%) incident cases and 9480 (24.5%) prevalent cases, AED treatment was not documented during 180 days or more of follow-up after diagnosis. Valproate (incident: 35 [5.81%]; prevalent: 514 [13.1%]) and phenytoin (incident: 33 [5.48%]; prevalent: 178 [4.53%]) were more commonly used for generalized epilepsy and oxcarbazepine (incident: 53 [8.03%]; prevalent: 386 [9.89%]) was more often used for focal epilepsy. Levetiracetam (incident: focal, 267 [40.5%]; generalized, 271 [45.0%]; prevalent: focal, 794 [20.3%]; generalized, 871 [22.2%]), lamotrigine (incident: focal, 123 [18.6%]; generalized, 106 [17.6%]; prevalent: focal, 968 [24.8%]; generalized, 871 [22.2%]), and topiramate (incident: focal, 102 [15.5%]; generalized, 64 [10.6%]; prevalent: focal, 499 [12.8%]; generalized, 470 [12.0%]) were leading AEDs prescribed for both focal and generalized epilepsy. Valproate was more commonly prescribed for women with comorbid headache or migraine (incident: 53 of 1251 [4.2%]; prevalent: 839 of 8046 [10.4%]), mood disorder (incident: 63 of 860 [7.3%]; prevalent: 1110 of 6995 [15.9%]), and anxiety and dissociative disorders (incident: 57 of 881 [6.5%]; prevalent: 798 of 5912 [13.5%]). Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26.8%]; prevalent: 2322 of 8046 [28.9%]). CONCLUSIONS AND RELEVANCE: Many women appear to be treated with valproate and topiramate despite known teratogenicity risks. Comorbidities may affect selecting certain AEDs despite their teratogenicity risks.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kim H, Faught E, Thurman DJ, et al. Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. JAMA Neurol. 2019. PMID: 30933252. doi:10.1001/jamaneurol.2019.0447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。